| |  |
| |
| | Domain structure of the MMP2.
Pre: signal sequence; Pro: propeptide with a free zinc-ligating thiol (SH) group; Zn: zinc-binding site; II: collagen-binding fibronectin type II inserts; H: hinge region;
The hemopexin/vitronectin-like domain contains four repeats with the first and last linked by a disulfide bond. |
| |
| Description | MMP2 is a Zn+2 dependent endopeptidase, synthesized and secreted in zymogen form. The nascent form of the protein shows an N-terminal signal sequence ("pre" domain) that directs the protein to the endoplasmic reticulum. The pre domain is followed by a propeptide-"pro" domain that maintains enzyme-latency until cleaved or disrupted, and a catalytic domain that contains the conserved zinc-binding region. A hemopexin/vitronectin-like domain is also seen, that is connected to the catalytic domain by a hinge or linker region. The hemopexin domain is involved in TIMP (Tissue Inhibitors of Metallo-Proteinases) binding, the binding of certain substrates, membrane activation, and some proteolytic activities. It also shows a series of three head-to-tail cysteine-rich repeats within its catalytic domain. These inserts resemble the collagen-binding type II repeats of fibronectin and are required to bind and cleave collagen and elastin. The regulation of MMP-2 activity occurs at many levels, of which regulation through TIMP-2 and its cell surface receptor, MT1-MMP (MMP14) is critically decisive. At higher levels of TIMP-2, MT1-MMP forms a ternary complex with MMP-2 through, leaving no free MT1-MMP receptors, thereby inhibiting the activation of pro-MMP-2 by MT1-MMP. But at lower levels of TIMP-2, due to availability of free MT1-MMP, MT1-MMP mediated activation of MMP-2 is observed. Further data also indicates that expression of TIMP-2, MMP-2 and MT1-MMP (MMP-14) is co-regulated transcriptionally, demonstrating an intricate network of regulation. Pro-MMP-2 activation is also seen by complex signaling induced by ECM proteins like osteopontin, various cytokines for example IL-8 in endothelial cells and other factors. |
| Expression | MMP2 is tightly regulated at the transcriptional and post-transcriptional levels. |
| Localisation | Peri/extracellular |
| Function | Primary function is degradation of proteins in the extracellular matrix. It proteolytically digests gelatin (denatured collagen), and types IV, V, VII, IX and X collagen. Physiologically, MMP-2 in coordination with other MMPs, play a role in normal tissue remodeling events such as embryonic development, angiogenesis, ovulation, mammary gland involution and wound healing. MMP2 is also involved in osteoblastic bone formation and/or inhibits osteoclastic bone resorption. |
| Homology | Homology in amino acid sequence is seen with the other members of Metalloproteinase family especially with MMP-9. |
| Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. |
| Bloomston M, Zervos EE, Rosemurgy AS 2nd |
| Annals of surgical oncology. 2002 ; 9 (7) : 668-674. |
| PMID 12167581 |
| |
| Activity of type IV collagenases in benign and malignant breast disease. |
| Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR |
| British journal of cancer. 1993 ; 67 (5) : 1126-1131. |
| PMID 8494711 |
| |
| Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. |
| Goldbach-Mansky R, Lee JM, Hoxworth JM, Smith D 2nd, Duray P, Schumacher RH Jr, Yarboro CH, Klippel J, Kleiner D, El-Gabalawy HS |
| Arthritis research. 2000 ; 2 (2) : 145-153. |
| PMID 11062605 |
| |
| An interactive computer graphics study of thermolysin-catalyzed peptide cleavage and inhibition by N-carboxymethyl dipeptides. |
| Hangauer DG, Monzingo AF, Matthews BW |
| Biochemistry. 1984 ; 23 (24) : 5730-5741. |
| PMID 6525336 |
| |
| The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. |
| John A, Tuszynski G |
| Pathology oncology research : POR. 2001 ; 7 (1) : 14-23. |
| PMID 11349215 |
| |
| Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. |
| Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK |
| Angiogenesis. 2005 ; 8 (1) : 63-71. |
| PMID 16132619 |
| |
| Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. |
| Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ |
| Nature genetics. 2001 ; 28 (3) : 261-265. |
| PMID 11431697 |
| |
| Matrix metalloproteinases as novel disease markers in Takayasu arteritis. |
| Matsuyama A, Sakai N, Ishigami M, Hiraoka H, Kashine S, Hirata A, Nakamura T, Yamashita S, Matsuzawa Y |
| Circulation. 2003 ; 108 (12) : 1469-1473. |
| PMID 12952836 |
| |
| Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. |
| Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, Tryggvason K |
| Science (New York, N.Y.). 1999 ; 284 (5420) : 1667-1670. |
| PMID 10356396 |
| |
| Matrix metalloproteinases in arthritic disease. |
| Murphy G, Knäuper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I |
| Arthritis research. 2002 ; 4 Suppl 3 : S39-S49. |
| PMID 12110122 |
| |
| Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. |
| Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y, Ikeda E |
| Investigative ophthalmology & visual science. 2003 ; 44 (5) : 2163-2170. |
| PMID 12714657 |
| |
| Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion. |
| Philip S, Bulbule A, Kundu GC |
| Glycoconjugate journal. 2004 ; 21 (8-9) : 429-441. |
| PMID 15750784 |
| |
| Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. |
| Philip S, Kundu GC |
| The Journal of biological chemistry. 2003 ; 278 (16) : 14487-14497. |
| PMID 12473670 |
| |
| Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. |
| Stetler-Stevenson WG |
| The Journal of clinical investigation. 1999 ; 103 (9) : 1237-1241. |
| PMID 10225966 |
| |
| Don't mess with the matrix. |
| Vu TH |
| Nature genetics. 2001 ; 28 (3) : 202-203. |
| PMID 11431682 |
| |
| Matrix Metalloproteinases and TIMPs. |
| Woessner JF, Nagase H |
| New York. : page Ox. |
| |
| Winchester syndrome caused by a homozygous mutation affecting the active site of matrix metalloproteinase 2. |
| Zankl A, Bonafé L, Calcaterra V, Di Rocco M, Superti-Furga A |
| Clinical genetics. 2005 ; 67 (3) : 261-266. |
| PMID 15691365 |
| |
| Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. |
| Zeng ZS, Cohen AM, Guillem JG |
| Carcinogenesis. 1999 ; 20 (5) : 749-755. |
| PMID 10334190 |
| |
